C
cell.com·this weekHallmarks of Aging: Updated 2023 Framework
Lopez-Otin et al. expand original hallmarks framework to 12 interconnected aging mechanisms, providing organizing structure for intervention research.
Cred
98
Auth
98
Fresh
76
Rel
88
Reasoning Engine
Conducting research…
- Discovering sourcesIdentified 6 candidate sources across 3 publication types.
- Analyzing sourcesExtracted atomic claims; scored credibility, recency, and bias on each.
- Cross-referencingDetected contradictions and reconciled overlapping claims.
- Synthesizing findingsCompressed claim graph into structural themes and a working thesis.
- Generating intelligenceDrafted executive brief, evidence map, risks, and recommendations.
Research Telemetry
live · demoReasoning
80/100
Confidence
76/100
Evidence
84/100
Depth
78/100
Diversity
84/100
Synthesized Answer
Map GLP-1 longevity-adjacent trial pipeline
GLP-1 longevity-adjacent trials span cardiovascular (SELECT, FLOW), neurodegenerative (Alzheimer's, Parkinson's), MASH/liver, addiction, and obesity-as-disease indications. Read-outs through 2027 will materially expand approved indications and effective TAM.
Key Points
- EVOKE (Alzheimer's) Phase 3 reading 2026 is the highest-impact catalyst
- Cardiovascular (SELECT, FLOW positive); kidney positive
- Retatrutide and oral formulations expand TAM materially
- Manufacturing fill/finish remains the supply bottleneck
- Lilly's multi-mechanism pipeline depth edges NovoNordisk
Knowledge Graph
11 nodes · 12 edgestopicconceptcompanyentity
Auto-generated Insights
Trend
GLP-1 receptor agonists are demonstrating longevity-adjacent benefits at scale.
Finding
Partial cellular reprogramming has cleared the tumorigenesis bar in mouse studies.
Signal
FDA acceptance of Loyal's canine longevity application opens regulatory pathway precedent.
Contradiction
Retail longevity-supplement market booms without clinical evidence base.
Structured Data
Cumulative longevity biotech capital
$11B
$3B YoYdisclosed, all-time
GLP-1 MACE risk reduction (SELECT)
−20%
vs placebonon-diabetic, CV disease
Clinical-stage company concentration
70%
of capital in 8 cos.Endpoints
Hallmarks of Aging (current)
12
vs 9 in 2013Cell, Lopez-Otin et al.
Sources6 ranked
Sorted by relevance
Research Paper
N
nejm.org·this weekSemaglutide and Cardiovascular Outcomes in Non-Diabetic Patients
SELECT trial: semaglutide reduced major adverse cardiovascular events by 20% in overweight, non-diabetic patients with existing CV disease.
Cred
98
Auth
98
Fresh
84
Rel
88
N
nature.com·this weekAltos Labs and Retro Biosciences Pipeline Update
Both companies focus on partial cellular reprogramming via Yamanaka factors; recent mouse studies show tissue rejuvenation without tumorigenesis.
Cred
97
Auth
96
Fresh
88
Rel
88
B
biocentury.com·this weekSenolytics Clinical Progress: Unity, BioAge, Cleara
Unity's UBX1325 advanced to Phase III for diabetic macular edema; BioAge's azelaprag in Phase II for obesity-related muscle loss.
Cred
86
Auth
85
Fresh
91
Rel
88
F
fda.gov·this weekLoyal and the Canine Aging Translation Pathway
FDA's Center for Veterinary Medicine has accepted Loyal's pharmaceutical for evaluation of reasonable expectation of effectiveness for canine lifespan extension.
Cred
97
Auth
98
Fresh
88
Rel
88
E
endpoints.com·this weekLongevity Biotech Funding Landscape 2026
Total disclosed longevity-biotech capital reached $11B cumulative; ~70% concentrated in 8 companies. Retail-product market remains evidence-light.
Cred
88
Auth
85
Fresh
94
Rel
88
Refine your research
Demo mode · All sources, insights, and data are mock-generated for illustration.